Abstract:R ed blood cells (RBCs) are nature’s long-circulating delivery vehicles. They possess various remarkable properties and continue to inspire the design and engineering of man-made delivery systems. Inherently suited for intravascular delivery, RBCs are intrinsically biocompatible, biodegradable, and nonimmunogenic. They form natural compartments capable of protecting encapsulated cargos, and this allows them to circulate in the bloodstream for a long period of time (up to 120 days). In addition, their semipermeable membrane affords sustained release to smallmolecule drugs, yet they are ideal for retaining large proteins while providing them access to the substrates. Delivery vehicles possessing one or several of these properties have long been desired for efficacious therapeutics. A long-sought strategy for RBC-mimicking delivery vehicles is to load natural RBCs with therapeutic agents without compromising the structural integrity and biological functions of the RBCs. Various loading techniques, including automated loading devices, have been developed to enable the encapsulation of payloads with molecular weights of over 180 kDa into RBCs with maintenance of the carriers’ biological competence. In addition to the interior of RBCs, their exterior surface has also been coupled with therapeutic molecules, either covalently or physically, for various delivery applications. These RBC-based delivery vehicles, namely carrier RBCs, have been developed for the delivery of numerous therapeutic agents, including proteins, nucleic acids, and small-molecule drugs. Several of them have entered clinical tests to treat various diseases, including cancers and enzyme deficiencies. Meanwhile, advances in molecular biology have provided unprecedented understanding of the connections between the physicochemical characteristics of RBCs and their biological functions. This understanding, in turn, has inspired researchers to model drug carriers after RBCs. Designs that mimic the physicochemical characteristics and biological functions of RBCs, particularly those that enable their passage through narrow constrictions while maintaining a long in vivo survival, have been integrated into the engineering of drug carriers and have resulted in novel delivery systems with improved drug tolerability, circulation lifetime, and efficacy. Recently, the pursuit of RBC-mimicking nanoparticles led us to develop an intriguing approach for functionalizing synthetic nanoparticles with natural RBC membranes. In this approach, we first collected intact cellular membranes and then coated them onto polymeric nanoparticle cores, such as those made from poly(lactic-co-glycolic acid) (PLGA); this resulted in red-blood-cell-membrane–coated nanoparticles (RBC-NPs; Figure 1). Our aim was to fabricate cellmimicking nanoparticles through a top-down approach that bypassed the labor-intensive processes of protein identification, purification, and conjugation. The natural membranes also provide a bilayered medium for transmembrane protein anchorage while preventing common chemical modifications that could compromise the integrity and functionalities of these proteins. The independent preparation of cellular membranes and particle cores before coating offers a new level of engineering flexibility toward highly functional biomimetic nanoparticles. Since their initial development, RBC-NPs have provided an unprecedented capability for harnessing the natural functionalities of native cells that would otherwise be difficult to replicate. They have since inspired us to develop novel nanotherapeutics for better disease intervention. In this Perspective, we review our recent progress in developing RBC-NPs for three distinct biomedical applications: long-circulating nanocarriers for drug delivery, biomimetic nanosponges for detoxification, and nanotoxoids for safe and effective toxin vaccination.

Red Blood Cell Membrane‐Coated Nanoparticles Enable Incompatible Blood Transfusions

Engineering red‐blood‐cell‐membrane–coated nanoparticles for broad biomedical applications

Red Blood Cell Membrane As a Biomimetic Nanocoating for Prolonged Circulation Time and Reduced Accelerated Blood Clearance.

Antigenically shielded universal red blood cells by polydopamine-based cell surface engineering

Prevention of Blood Incompatibility Related Hemagglutination: Blocking of Antigen A on Red Blood Cells Using In Silico Designed Recombinant Anti-A scFv

Synthetic Nanoparticles Camouflaged with Biomimetic Erythrocyte Membranes for Reduced Reticuloendothelial System Uptake

Biomimetic Recombinant of Red Blood Cell Membranes for Improved Photothermal Therapy

Red-blood-cell-mimetic Gene Delivery Systems for Long Circulation and High Transfection Efficiency in ECs.

Erythrocyte-Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization.

Massive transfusion of incompatible red blood cells: A case report demonstrating the benefits of a regional patient alloantibody registry and prompt automated red cell exchange

Nanomaterial-Enhanced Red Blood Cell Biopreservation: from Refrigeration to Cryopreservation.

Red Blood Cell–derived Nanoerythrosome for Antigen Delivery with Enhanced Cancer Immunotherapy

Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation

Biomimetic Nanoemulsions for Oxygen Delivery in Vivo

Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes

Cell Membrane-Camouflaged Nanocarriers with Biomimetic Deformability of Erythrocytes for Ultralong Circulation and Enhanced Cancer Therapy

Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies

Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude

Surface-anchored Framework for Generating RhD-epitope Stealth Red Blood Cells

In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source

Genetic Engineering of Transfusable Platelets with mRNA-Lipid Nanoparticles is Compatible with Blood Banking Practices